A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3009 in Participants with Gastrointestinal Stromal Tumors (GIST)

Disease Sites:

Colon, Esophageal, GIST, Gastric/Gastroesophageal, Gastrointestinal, Liver, Pancreatic, Rectal

Staging:

Phase I/II

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

DCC-3009

Principal Investigator(s):

Keedy, Vicki

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

09-17-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTSAR24137P

National Clinical Trial ID:

NCT06630234

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available